Analysts at H.C. Wainwright Reiterated their Buy rating for Abeona Therapeutics (ABEO) with $30.0000 PT; Carlson Capital LP Has Boosted Sun Cmntys (SUI) Position

April 2, 2018 - By Danny Collins

Sun Communities, Inc. (NYSE:SUI) Logo

Carlson Capital LP increased Sun Cmntys Inc (SUI) stake by 2.88% reported in 2017Q4 SEC filing. Carlson Capital LP acquired 4,512 shares as Sun Cmntys Inc (SUI)’s stock declined 1.59%. The Carlson Capital LP holds 160,950 shares with $14.93M value, up from 156,438 last quarter. Sun Cmntys Inc now has $7.55B valuation. The stock increased 0.35% or $0.32 during the last trading session, reaching $91.37. About 536,585 shares traded or 23.03% up from the average. Sun Communities, Inc. (NYSE:SUI) has risen 13.44% since April 2, 2017 and is uptrending. It has outperformed by 1.89% the S&P500.

New York: In an analyst report shared with investors and clients on Monday morning, H.C. Wainwright reiterated their Buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO). They currently have a $30.0000 price target on the firm. H.C. Wainwright’s target indicates a potential upside of 109.06% from the company’s previous close.

Among 5 analysts covering Sun Communities (NYSE:SUI), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Sun Communities had 17 analyst reports since August 12, 2015 according to SRatingsIntel. Robert W. Baird maintained Sun Communities, Inc. (NYSE:SUI) on Monday, October 16 with “Buy” rating. BMO Capital Markets maintained it with “Buy” rating and $96.0 target in Monday, October 23 report. On Wednesday, August 12 the stock rating was upgraded by Zacks to “Sell”. The rating was maintained by RBC Capital Markets with “Buy” on Friday, July 14. The rating was maintained by BMO Capital Markets on Wednesday, February 21 with “Buy”. BMO Capital Markets maintained Sun Communities, Inc. (NYSE:SUI) rating on Tuesday, January 9. BMO Capital Markets has “Buy” rating and $97.0 target. On Friday, January 5 the stock rating was downgraded by Robert W. Baird to “Neutral”. The firm has “Buy” rating by Robert W. Baird given on Friday, September 8. The firm earned “Outperform” rating on Monday, December 4 by Evercore. Robert W. Baird upgraded Sun Communities, Inc. (NYSE:SUI) on Wednesday, March 30 to “Outperform” rating.

Since February 23, 2018, it had 0 insider purchases, and 1 insider sale for $193,248 activity. Shares for $193,248 were sold by LEWIS CLUNET R.

Carlson Capital LP decreased Noble Energy Inc (NYSE:NBL) stake by 298,726 shares to 620,721 valued at $18.09M in 2017Q4. It also reduced Sprouts Fmrs Mkt Inc (NASDAQ:SFM) stake by 172,506 shares and now owns 320,802 shares. Texas Capital Bancshares Inc (NASDAQ:TCBI) was reduced too.

Investors sentiment decreased to 1.27 in 2017 Q4. Its down 0.23, from 1.5 in 2017Q3. It worsened, as 24 investors sold SUI shares while 74 reduced holdings. 32 funds opened positions while 92 raised stakes. 74.09 million shares or 0.89% more from 73.44 million shares in 2017Q3 were reported. 12,555 are owned by Blair William & Com Il. Connecticut-based Quantitative Systematic Strategies Ltd Llc has invested 0.17% in Sun Communities, Inc. (NYSE:SUI). Green Street Invsts Limited Liability Com stated it has 54,700 shares. Royal Savings Bank Of Canada holds 0% or 81,842 shares in its portfolio. Amer Century Cos has invested 0.06% in Sun Communities, Inc. (NYSE:SUI). Reilly Fin Ltd Limited Liability Company holds 0% of its portfolio in Sun Communities, Inc. (NYSE:SUI) for 211 shares. Brinker stated it has 0.04% of its portfolio in Sun Communities, Inc. (NYSE:SUI). Ww Asset Mngmt reported 3,890 shares. Macquarie Group Inc Limited holds 0% or 28,500 shares in its portfolio. Amp Invsts Limited holds 0.31% in Sun Communities, Inc. (NYSE:SUI) or 618,803 shares. State Common Retirement Fund holds 0.02% of its portfolio in Sun Communities, Inc. (NYSE:SUI) for 170,300 shares. Dupont Capital Mgmt reported 10,696 shares or 0.02% of all its holdings. Advantus Cap Mgmt reported 270,896 shares. Strs Ohio has 0.04% invested in Sun Communities, Inc. (NYSE:SUI). Fort Washington Invest Advisors Oh invested in 0% or 2,500 shares.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $677.71 million. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

Among 10 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics has $36.0 highest and $6.0 lowest target. $26.50’s average target is 84.67% above currents $14.35 stock price. Abeona Therapeutics had 37 analyst reports since December 16, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Thursday, June 1. The rating was maintained by Maxim Group with “Buy” on Tuesday, August 29. Jefferies maintained the stock with “Buy” rating in Friday, October 6 report. H.C. Wainwright maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) on Monday, September 18 with “Buy” rating. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, March 20. The rating was reinitiated by Rodman & Renshaw on Wednesday, April 20 with “Buy”. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, July 19. On Monday, January 29 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm earned “Buy” rating on Thursday, August 24 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Monday, October 16.

The stock increased 5.13% or $0.7 during the last trading session, reaching $14.35. About 716,366 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 188.66% since April 2, 2017 and is uptrending. It has outperformed by 177.11% the S&P500.

Sun Communities, Inc. (NYSE:SUI) Institutional Positions Chart